1
|
Ding K, Chen F, Priedigkeit N, Brown DD, Weiss K, Watters R, Levine KM, Heim T, Li W, Hooda J, Lucas PC, Atkinson JM, Oesterreich S, Lee AV. Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine. Ann Oncol 2022; 33:1085-1088. [PMID: 35764274 PMCID: PMC10007959 DOI: 10.1016/j.annonc.2022.06.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Revised: 05/04/2022] [Accepted: 06/17/2022] [Indexed: 11/26/2022] Open
Affiliation(s)
- K Ding
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, USA; Integrative Systems Biology Program, University of Pittsburgh, Pittsburgh, USA
| | - F Chen
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Tsinghua University, Beijing, China
| | - N Priedigkeit
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
| | - D D Brown
- Institute for Precision Medicine, University of Pittsburgh and UPMC, Pittsburgh, USA
| | - K Weiss
- Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, USA; Musculoskeletal Oncology Laboratory, University of Pittsburgh, Pittsburgh, USA
| | - R Watters
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, USA; Musculoskeletal Oncology Laboratory, University of Pittsburgh, Pittsburgh, USA
| | - K M Levine
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA
| | - T Heim
- Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, USA; Musculoskeletal Oncology Laboratory, University of Pittsburgh, Pittsburgh, USA
| | - W Li
- Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, USA
| | - J Hooda
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, USA
| | - P C Lucas
- Department of Pathology, University of Pittsburgh, Pittsburgh, USA
| | - J M Atkinson
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, USA; Institute for Precision Medicine, University of Pittsburgh and UPMC, Pittsburgh, USA
| | - S Oesterreich
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, USA.
| | - A V Lee
- Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, USA; Institute for Precision Medicine, University of Pittsburgh and UPMC, Pittsburgh, USA.
| |
Collapse
|
2
|
Sokol ES, Feng YX, Jin DX, Basudan A, Lee AV, Atkinson JM, Chen J, Stephens PJ, Frampton GM, Gupta PB, Ross JS, Chung JH, Oesterreich S, Ali SM, Hartmaier RJ. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer. Ann Oncol 2020; 30:115-123. [PMID: 30423024 PMCID: PMC6336006 DOI: 10.1093/annonc/mdy497] [Citation(s) in RCA: 49] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Background Invasive lobular carcinoma (ILC) as a disease entity distinct from invasive ductal carcinoma (IDC) has merited focused studies of the genomic landscape, but those to date are largely limited to the assessment of early-stage cancers. Given that genomic alterations develop as acquired resistance to endocrine therapy, studies on refractory ILC are needed. Patients and methods Tissue from 336 primary-enriched, breast-biopsied ILC and 485 estrogen receptor (ER)-positive IDC and metastatic biopsy specimens from 180 ILC and 191 ER-positive IDC patients was assayed with hybrid-capture-based comprehensive genomic profiling for short variant, indel, copy number variants, and rearrangements in up to 395 cancer-related genes. Results Whereas ESR1 alterations are enriched in the metastases of both ILC and IDC compared with breast specimens, NF1 alterations are enriched only in ILC metastases (mILC). NF1 alterations are predominantly under loss of heterozygosity (11/14, 79%), are mutually exclusive with ESR1 mutations [odds ratio = 0.24, P < 0.027] and are frequently polyclonal in ctDNA assays. Assessment of paired specimens shows that NF1 alterations arise in the setting of acquired resistance. An in vitro model of CDH1 mutated ER-positive breast cancer demonstrates that NF1 knockdown confers a growth advantage in the presence of 4-hydroxy tamoxifen. Our study further identified a significant increase in tumor mutational burden (TMB) in mILCs relative to breast ILCs or metastatic IDCs (8.9% >20 mutations/mb; P < 0.001). Most TMB-high mILCs harbor an APOBEC trinucleotide signature (14/16; 88%). Conclusions This study identifies alteration of NF1 as enriched specifically in mILC. Mutual exclusivity with ESR1 alterations, polyclonality in relapsed ctDNA, and de novo acquisition suggest a role for NF1 loss in endocrine therapy resistance. Since NF1 loss leads to RAS/RAF kinase activation, patients may benefit from a matched inhibitor. Moreover, for an independent subset of mILC, TMB was elevated relative to breast ILC, suggesting possible benefit from immune checkpoint inhibitors.
Collapse
Affiliation(s)
- E S Sokol
- Foundation Medicine Inc., Cambridge.
| | - Y X Feng
- Department of Biology, Massachusetts Institute of Technology, Cambridge
| | - D X Jin
- Foundation Medicine Inc., Cambridge; Department of Biology, Massachusetts Institute of Technology, Cambridge
| | - A Basudan
- University of Pittsburgh, Pittsburgh; Womens Cancer Research Center, Department of Genetics, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh
| | - A V Lee
- University of Pittsburgh, Pittsburgh; Womens Cancer Research Center, Department of Pharmacology and Chemical Biology, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh
| | - J M Atkinson
- University of Pittsburgh, Pittsburgh; Womens Cancer Research Center, Department of Pharmacology and Chemical Biology, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh
| | - J Chen
- University of Pittsburgh, Pittsburgh; Womens Cancer Research Center, Department of Pharmacology and Chemical Biology, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh
| | | | | | - P B Gupta
- Department of Biology, Massachusetts Institute of Technology, Cambridge
| | - J S Ross
- Foundation Medicine Inc., Cambridge; Upstate Medical University, Syracuse, USA
| | | | - S Oesterreich
- University of Pittsburgh, Pittsburgh; Womens Cancer Research Center, Department of Pharmacology and Chemical Biology, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh
| | - S M Ali
- Foundation Medicine Inc., Cambridge
| | | |
Collapse
|
3
|
Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, Morley S, Rosenzweig M, Gay LM, Goldberg ME, Suh J, Ali SM, Ross J, Leyland-Jones B, Young B, Williams C, Park B, Tsai M, Haley B, Peguero J, Callahan RD, Sachelarie I, Cho J, Atkinson JM, Bahreini A, Nagle AM, Puhalla SL, Watters RJ, Erdogan-Yildirim Z, Cao L, Oesterreich S, Mathew A, Lucas PC, Davidson NE, Brufsky AM, Frampton GM, Stephens PJ, Chmielecki J, Lee AV. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann Oncol 2019; 29:872-880. [PMID: 29360925 PMCID: PMC5913625 DOI: 10.1093/annonc/mdy025] [Citation(s) in RCA: 62] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Background Estrogen receptor-positive (ER-positive) metastatic breast cancer is often intractable due to endocrine therapy resistance. Although ESR1 promoter switching events have been associated with endocrine-therapy resistance, recurrent ESR1 fusion proteins have yet to be identified in advanced breast cancer. Patients and methods To identify genomic structural rearrangements (REs) including gene fusions in acquired resistance, we undertook a multimodal sequencing effort in three breast cancer patient cohorts: (i) mate-pair and/or RNAseq in 6 patient-matched primary-metastatic tumors and 51 metastases, (ii) high coverage (>500×) comprehensive genomic profiling of 287-395 cancer-related genes across 9542 solid tumors (5216 from metastatic disease), and (iii) ultra-high coverage (>5000×) genomic profiling of 62 cancer-related genes in 254 ctDNA samples. In addition to traditional gene fusion detection methods (i.e. discordant reads, split reads), ESR1 REs were detected from targeted sequencing data by applying a novel algorithm (copyshift) that identifies major copy number shifts at rearrangement hotspots. Results We identify 88 ESR1 REs across 83 unique patients with direct confirmation of 9 ESR1 fusion proteins (including 2 via immunoblot). ESR1 REs are highly enriched in ER-positive, metastatic disease and co-occur with known ESR1 missense alterations, suggestive of polyclonal resistance. Importantly, all fusions result from a breakpoint in or near ESR1 intron 6 and therefore lack an intact ligand binding domain (LBD). In vitro characterization of three fusions reveals ligand-independence and hyperactivity dependent upon the 3' partner gene. Our lower-bound estimate of ESR1 fusions is at least 1% of metastatic solid breast cancers, the prevalence in ctDNA is at least 10× enriched. We postulate this enrichment may represent secondary resistance to more aggressive endocrine therapies applied to patients with ESR1 LBD missense alterations. Conclusions Collectively, these data indicate that N-terminal ESR1 fusions involving exons 6-7 are a recurrent driver of endocrine therapy resistance and are impervious to ER-targeted therapies.
Collapse
Affiliation(s)
- R J Hartmaier
- Foundation Medicine Inc., Cambridge; Department of Pharmacology and Chemical Biolog, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA; Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA.
| | | | - N Priedigkeit
- Department of Pharmacology and Chemical Biolog, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA; Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA
| | | | | | | | - S Morley
- Foundation Medicine Inc., Cambridge
| | | | - L M Gay
- Foundation Medicine Inc., Cambridge
| | | | - J Suh
- Foundation Medicine Inc., Cambridge
| | - S M Ali
- Foundation Medicine Inc., Cambridge
| | - J Ross
- Foundation Medicine Inc., Cambridge
| | - B Leyland-Jones
- Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, USA
| | - B Young
- Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, USA
| | - C Williams
- Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, USA
| | - B Park
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, USA
| | - M Tsai
- Minnesota Oncology, Minneapolis, USA
| | - B Haley
- UT Southwestern Medical Center, Dallas, USA
| | - J Peguero
- Oncology Consultants Research Department, Houston, USA
| | | | | | - J Cho
- New Bern Cancer Care, New Bern, USA
| | - J M Atkinson
- Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA
| | - A Bahreini
- Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA; Department of Human Genetics, University of Pittsburgh, Pittsburgh, USA; Department of Genetics and Molecular Biology, Isfahan University of Medical Sciences, Isfahan, Iran
| | - A M Nagle
- Department of Pharmacology and Chemical Biolog, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA; Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA
| | - S L Puhalla
- Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA; Foundation Medicine Inc., Cambridge; Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, USA
| | - R J Watters
- Department of Pharmacology and Chemical Biolog, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA; Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA; Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, USA
| | - Z Erdogan-Yildirim
- Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA; Department of Human Genetics, University of Pittsburgh, Pittsburgh, USA
| | - L Cao
- Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA; Central South University Xiangya School of Medicine, China
| | - S Oesterreich
- Department of Pharmacology and Chemical Biolog, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA; Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA
| | - A Mathew
- Department of Medicine, University of Pittsburgh, Pittsburgh, USA
| | - P C Lucas
- Department of Pathology, University of Pittsburgh, Pittsburgh, USA
| | - N E Davidson
- Foundation Medicine Inc., Cambridge; Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, USA
| | - A M Brufsky
- Foundation Medicine Inc., Cambridge; Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, USA
| | | | | | | | - A V Lee
- Department of Pharmacology and Chemical Biolog, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA; Women's Cancer Research Center, Magee-Women's Research Institute, Pittsburgh, USA
| |
Collapse
|
4
|
Li Z, Bahreini A, Levine KM, Wang P, Tasdemir N, Montanez MA, Sundd P, Wallace CT, Watkins SC, Chu D, Park BH, Hou W, Mooring MS, Zhu L, Tseng GC, Carroll JS, Atkinson JM, Lee AV, Oesterreich S. Abstract P2-01-09: ESR1 mutations drive breast cancer metastasis by context-dependent alterations in adhesive and migratory properties. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-01-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Estrogen receptor alpha (ERα/ESR1) is mutated in 30-40% of endocrine resistant ER+ breast cancer. These mutations, primarily located in the ligand binding domain, are associated with worse outcome in patients, and preclinical studies have shown that they cause ligand independent growth. An open question is whether these mutations contribute to actual metastatic process, or merely endocrine resistance.
Methods: Using Y537S and D538G genome-edited MCF7 and T47D cells, 3D growth was assessed in ultralow attachment plates. Cell-cell adhesion was determined using calcein-labelled adhesion assay and quantitative microfluidic fluorescence microscope (qMFM). Collagen-based adhesion and spheroid invasion assays were used to test adhesive and invasive properties. Wound scratching, spheroid collective migration and Boyden chamber transwell assays were applied to monitor cell migratory phenotypes. Mutated ER cistromes were profiled using ChIP-sequencing. ESR1 mutations in clinical samples were characterized using ddPCR.
Results: Visual inspection of cells grown in suspension culture revealed more compressed multicellular spheroids in ESR1 mutant cells, indicative of increased cell-cell interactions. This observation was confirmed in both static and microfluidic conditions. This effect was more pronounced in MCF7 than T47D cells, correlating with increased expression of desmosome and gap junction genes. Pharmacological blockade of gap junctions decreased cell-cell adhesion. Decreased attachment and increased invasion to collagen were discerned in all mutant cell types. Further functional analysis identified alterations in the TIMP3-MMP axis causing these phenotypes. The cell-cell adhesion phenotypes were restricted to MCF7-Y537S/D538G and T47D-Y537S, whereas T47D-D538G cells showed significantly increased migration. A GSEA screen identified Wnt signaling as uniquely induced in this context, and combination treatment using the Wnt inhibitor LGK974 and Fulvestrant led to synergistic inhibition of migration. ChIP-seq identified mutation-specific cistromes with an overall increased ligand-independent ER binding. However, it did not reveal binding sites in any candidate metastases genes, suggesting secondary epigenetic mechanisms. The motif analysis revealed the enrichment of FOXA1 motifs in mutated ER cistromes except T47D-D538G cells. However, knockdown of FOXA1 induced significantly higher inhibition of T47D-D538G migration than Fulvestrant treatment alone, indicating a FOXA1-dominated mechanism. Collectively, these data show that ESR1 mutant cells gain metastatic properties, in addition to endocrine resistance. To prove this using clinical samples, we measured ESR1 mutations in a well-defined cohort of endocrine resistant local or distant recurrence. Significant enrichment of ESR1 mutations in distant (9/55) vs local (0/27) recurrences confirms critical role of mutant ERα in metastases.
Conclusion: Further analysis of context dependent changes in cell-cell adhesion and migration of ESR1 mutant cells might guide the design and development of drugs targeting ERα-mutant tumors, such as inhibitors of gap junction, FOXA1, MMP, and Wnt signaling pathways.
Disclosure: The authors declare no conflict of interest.
Citation Format: Li Z, Bahreini A, Levine KM, Wang P, Tasdemir N, Montanez MA, Sundd P, Wallace CT, Watkins SC, Chu D, Park BH, Hou W, Mooring MS, Zhu L, Tseng GC, Carroll JS, Atkinson JM, Lee AV, Oesterreich S. ESR1 mutations drive breast cancer metastasis by context-dependent alterations in adhesive and migratory properties [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-01-09.
Collapse
Affiliation(s)
- Z Li
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - A Bahreini
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - KM Levine
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - P Wang
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - N Tasdemir
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - MA Montanez
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - P Sundd
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - CT Wallace
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - SC Watkins
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - D Chu
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - BH Park
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - W Hou
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - MS Mooring
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - L Zhu
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - GC Tseng
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - JS Carroll
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - JM Atkinson
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - AV Lee
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| | - S Oesterreich
- University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; Tsinghua University, Pittsburgh, PA; Johns Hopkins University, Baltimore, MD; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
| |
Collapse
|
5
|
Atkinson JM, Cao L, Basudan A, Sikora MJ, Bahreini A, Tasdemir N, Jankowitz RC, McAuliffe PF, Dabbs D, Haupt S, Haupt Y, Peter Lucas PC, Lee AV, Oesterreich S. Abstract P3-06-03: Copy number analysis identifies ESR1 and MDM4 as drivers of progression in invasive lobular breast carcinoma. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-06-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Invasive lobular carcinoma (ILC) is the second most common histological subtype of breast cancer after invasive ductal carcinoma (IDC). While specific clinical and pathological features differ between ILC and IDC, both histologies are treated the same, due to a lack of knowledge of targetable pathways underlying the observed differences. To identify potential genetic drivers of ILC progression, we set out to identify genes with copy number (CN) alterations, comparing tumors with good outcome to those with poor outcome.
Method: We designed probes for a total of 67 genes known to be frequently altered in breast cancer and used sensitive nanoString technology to comprehensively investigate CN alterations of these genes in 70 well-curated primary ILCs. ILC cell lines MDA-MB-134-VI, SUM44PE, and BCK4 were used for functional studies including proliferation, apoptosis, colony formation, and analysis of gene expression.
Results: Our studies reveal that ESR1 is frequently amplified in primary ILC (14% gains and 10% amplification), and that tumors with amplified ESR1 are more likely to recur compared to those with normal CN. Our analysis also identified a subset of ILCs with HER2 amplification (19%) despite a negative clinical IHC score, and these tumors expressed high HER2 mRNA, protein, and demonstrated enrichment of a molecular HER2 signature. The other most frequently amplified genes included CCND1 (33%), MDM4 (17%), and MYC (17%), and most frequently lost genes were NCOR2 (7%), FGFR4 (6%) and TP53 (6%). MDM4, a negative regulator of p53, has previously been reported to play a role in breast cancer, though little is known about its role in ILC. We demonstrate that decreasing MDM4 levels in p53 wild type ILC cell lines results in increased apoptosis, decreased proliferation associated with cell cycle arrest, and activation of p53 target genes. Intriguingly, a similar induction of G0/G1 cell cycle arrest and increase in apoptosis was observed in p53 mutant ILC cells after MDM4 downregulation, suggesting a p53-independent function of MDM4.
Conclusion: Sensitive detection of CN changes identified amplifications of ESR1 and MDM4 as potential drivers of ILC. Functional studies demonstrate that MDM4 has both p53 dependent and independent functions that warrant further study.
Citation Format: Atkinson JM, Cao L, Basudan A, Sikora MJ, Bahreini A, Tasdemir N, Jankowitz RC, McAuliffe PF, Dabbs D, Haupt S, Haupt Y, Peter Lucas PC, Lee AV, Oesterreich S. Copy number analysis identifies ESR1 and MDM4 as drivers of progression in invasive lobular breast carcinoma [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-06-03.
Collapse
Affiliation(s)
- JM Atkinson
- Womens Cancer Research Center, University of Pittsburgh, Pittsburgh, PA; Third Xiangya Hospital, Central South University, Changsha, China; University of Pittsburgh, Pittsburgh, PA; University of Colorado Anschutz Medical Campus, Aurora, CO; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran; UPMC Hillman Cancer Center, Pittsburgh, PA; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - L Cao
- Womens Cancer Research Center, University of Pittsburgh, Pittsburgh, PA; Third Xiangya Hospital, Central South University, Changsha, China; University of Pittsburgh, Pittsburgh, PA; University of Colorado Anschutz Medical Campus, Aurora, CO; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran; UPMC Hillman Cancer Center, Pittsburgh, PA; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - A Basudan
- Womens Cancer Research Center, University of Pittsburgh, Pittsburgh, PA; Third Xiangya Hospital, Central South University, Changsha, China; University of Pittsburgh, Pittsburgh, PA; University of Colorado Anschutz Medical Campus, Aurora, CO; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran; UPMC Hillman Cancer Center, Pittsburgh, PA; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - MJ Sikora
- Womens Cancer Research Center, University of Pittsburgh, Pittsburgh, PA; Third Xiangya Hospital, Central South University, Changsha, China; University of Pittsburgh, Pittsburgh, PA; University of Colorado Anschutz Medical Campus, Aurora, CO; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran; UPMC Hillman Cancer Center, Pittsburgh, PA; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - A Bahreini
- Womens Cancer Research Center, University of Pittsburgh, Pittsburgh, PA; Third Xiangya Hospital, Central South University, Changsha, China; University of Pittsburgh, Pittsburgh, PA; University of Colorado Anschutz Medical Campus, Aurora, CO; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran; UPMC Hillman Cancer Center, Pittsburgh, PA; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - N Tasdemir
- Womens Cancer Research Center, University of Pittsburgh, Pittsburgh, PA; Third Xiangya Hospital, Central South University, Changsha, China; University of Pittsburgh, Pittsburgh, PA; University of Colorado Anschutz Medical Campus, Aurora, CO; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran; UPMC Hillman Cancer Center, Pittsburgh, PA; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - RC Jankowitz
- Womens Cancer Research Center, University of Pittsburgh, Pittsburgh, PA; Third Xiangya Hospital, Central South University, Changsha, China; University of Pittsburgh, Pittsburgh, PA; University of Colorado Anschutz Medical Campus, Aurora, CO; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran; UPMC Hillman Cancer Center, Pittsburgh, PA; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - PF McAuliffe
- Womens Cancer Research Center, University of Pittsburgh, Pittsburgh, PA; Third Xiangya Hospital, Central South University, Changsha, China; University of Pittsburgh, Pittsburgh, PA; University of Colorado Anschutz Medical Campus, Aurora, CO; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran; UPMC Hillman Cancer Center, Pittsburgh, PA; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - D Dabbs
- Womens Cancer Research Center, University of Pittsburgh, Pittsburgh, PA; Third Xiangya Hospital, Central South University, Changsha, China; University of Pittsburgh, Pittsburgh, PA; University of Colorado Anschutz Medical Campus, Aurora, CO; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran; UPMC Hillman Cancer Center, Pittsburgh, PA; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - S Haupt
- Womens Cancer Research Center, University of Pittsburgh, Pittsburgh, PA; Third Xiangya Hospital, Central South University, Changsha, China; University of Pittsburgh, Pittsburgh, PA; University of Colorado Anschutz Medical Campus, Aurora, CO; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran; UPMC Hillman Cancer Center, Pittsburgh, PA; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - Y Haupt
- Womens Cancer Research Center, University of Pittsburgh, Pittsburgh, PA; Third Xiangya Hospital, Central South University, Changsha, China; University of Pittsburgh, Pittsburgh, PA; University of Colorado Anschutz Medical Campus, Aurora, CO; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran; UPMC Hillman Cancer Center, Pittsburgh, PA; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - PC Peter Lucas
- Womens Cancer Research Center, University of Pittsburgh, Pittsburgh, PA; Third Xiangya Hospital, Central South University, Changsha, China; University of Pittsburgh, Pittsburgh, PA; University of Colorado Anschutz Medical Campus, Aurora, CO; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran; UPMC Hillman Cancer Center, Pittsburgh, PA; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - AV Lee
- Womens Cancer Research Center, University of Pittsburgh, Pittsburgh, PA; Third Xiangya Hospital, Central South University, Changsha, China; University of Pittsburgh, Pittsburgh, PA; University of Colorado Anschutz Medical Campus, Aurora, CO; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran; UPMC Hillman Cancer Center, Pittsburgh, PA; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - S Oesterreich
- Womens Cancer Research Center, University of Pittsburgh, Pittsburgh, PA; Third Xiangya Hospital, Central South University, Changsha, China; University of Pittsburgh, Pittsburgh, PA; University of Colorado Anschutz Medical Campus, Aurora, CO; School of Medicine, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran; UPMC Hillman Cancer Center, Pittsburgh, PA; Peter MacCallum Cancer Centre, Melbourne, Australia
| |
Collapse
|
6
|
Kurter C, Finck ADK, Huemiller ED, Medvedeva J, Weis A, Atkinson JM, Qiu Y, Shen L, Lee SH, Vojta T, Ghaemi P, Hor YS, Van Harlingen DJ. Conductance Spectroscopy of Exfoliated Thin Flakes of Nb xBi 2Se 3. Nano Lett 2019; 19:38-45. [PMID: 30481037 DOI: 10.1021/acs.nanolett.8b02954] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
We study unconventional superconductivity in exfoliated single crystals of a promising three-dimensional (3D) topological superconductor candidate, Nb-doped Bi2Se3 through differential conductance spectroscopy and magneto-transport. The strong anisotropy of the critical field along the out-of-plane direction suggests that the thin exfoliated flakes are in the quasi-2D limit. Normal metal-superconductor (NS) contacts with either high or low transparencies made by depositing gold leads onto Nb-doped Bi2Se3 flakes both show significant enhancement in zero bias conductance and coherence dips at the superconducting energy gap. Such behavior is inconsistent with conventional Blonder-Tinkham-Klapwijk theory. Instead, we discuss how our results are consistent with p-wave pairing symmetry, supporting the possibility of topological superconductivity in Nb-doped Bi2Se3. Finally, we observe signatures of multiple superconducting energy gaps, which could originate from multiple Fermi surfaces reported earlier in bulk crystals.
Collapse
Affiliation(s)
- C Kurter
- Department of Physics and Materials Research Center , Missouri University of Science and Technology , Rolla , Missouri 65409 , United States
- Department of Physics and Materials Research Laboratory , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States
| | - A D K Finck
- Department of Physics and Materials Research Laboratory , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States
| | - E D Huemiller
- Department of Physics and Materials Research Laboratory , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States
| | - J Medvedeva
- Department of Physics and Materials Research Center , Missouri University of Science and Technology , Rolla , Missouri 65409 , United States
| | - A Weis
- Department of Physics and Materials Research Laboratory , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States
| | - J M Atkinson
- Department of Physics and Materials Research Laboratory , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States
| | - Y Qiu
- Department of Physics and Materials Research Center , Missouri University of Science and Technology , Rolla , Missouri 65409 , United States
| | - L Shen
- Department of Physics and Materials Research Center , Missouri University of Science and Technology , Rolla , Missouri 65409 , United States
| | - S H Lee
- Department of Physics and Materials Research Center , Missouri University of Science and Technology , Rolla , Missouri 65409 , United States
| | - T Vojta
- Department of Physics and Materials Research Center , Missouri University of Science and Technology , Rolla , Missouri 65409 , United States
| | - P Ghaemi
- Department of Physics , City College of New of CUNY , New York , New York 10031 , United States
- Department of Physics , Graduate Center of CUNY , New York , New York 10016 , United States
| | - Y S Hor
- Department of Physics and Materials Research Center , Missouri University of Science and Technology , Rolla , Missouri 65409 , United States
| | - D J Van Harlingen
- Department of Physics and Materials Research Laboratory , University of Illinois at Urbana-Champaign , Urbana , Illinois 61801 , United States
| |
Collapse
|
7
|
Atkinson JM, Garner HC. Least restrictive alternative – advance statements and the new mental health legislation. Psychiatr bull 2018. [DOI: 10.1192/pb.26.7.246] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Proposals for new mental health legislation make the case for using the ‘least restrictive alternative’ (Scottish Executive, 2001) and the ‘least restrictive environment’ (Department of Health & Home Office, 2000) as guiding principles in deciding the management and treatment of the patient. This appears to be the case made for introducing compulsory treatment in the community. The patient living in the community, while maintained on medication, rather than the hospital would appear to be defined as on the ‘least restrictive alternative’. This, however, takes only a limited approach to what is ‘restrictive’, which should be interpreted more widely, including the patient's view as well as that of clinicians and policy makers. Thus, a patient may see it as less restrictive during an acute phase to be in hospital and not on medication, than in the community but on medication. It is likely, given our knowledge of patients' attitudes to medication (Eastwood & Pugh, 1997), that many patients will prefer to be on oral medication rather than depot, which they see as less restrictive.
Collapse
|
8
|
Daryani VM, Patel YT, Tagen M, Turner DC, Carcaboso AM, Atkinson JM, Gajjar A, Gilbertson RJ, Wright KD, Stewart CF. Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma. CPT Pharmacometrics Syst Pharmacol 2016; 5:211-221. [PMID: 27104090 PMCID: PMC4834132 DOI: 10.1002/psp4.12075] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Accepted: 03/03/2016] [Indexed: 12/11/2022]
Abstract
We previously investigated novel therapies for pediatric ependymoma and found 5‐fluorouracil (5‐FU) i.v. bolus increased survival in a representative mouse model. However, without a quantitative framework to derive clinical dosing recommendations, we devised a translational pharmacokinetic‐pharmacodynamic (PK‐PD) modeling and simulation approach. Results from our preclinical PK‐PD model suggested tumor concentrations exceeded the 1‐hour target exposure (in vitro IC90), leading to tumor growth delay and increased survival. Using an adult population PK model, we scaled our preclinical PK‐PD model to children. To select a 5‐FU dosage for our clinical trial in children with ependymoma, we simulated various 5‐FU dosages for tumor exposures and tumor growth inhibition, as well as considering tolerability to bolus 5‐FU administration. We developed a pediatric population PK model of bolus 5‐FU and simulated tumor exposures for our patients. Simulations for tumor concentrations indicated that all patients would be above the 1‐hour target exposure for antitumor effect.
Collapse
Affiliation(s)
- V M Daryani
- Department of Pharmaceutical Sciences St. Jude Children's Research Hospital Memphis Tennessee USA
| | - Y T Patel
- Department of Pharmaceutical Sciences St. Jude Children's Research Hospital Memphis Tennessee USA
| | - M Tagen
- Genentech South San Francisco California USA
| | - D C Turner
- Quantitative Pharmacology and Pharmacometrics Merck Research Laboratories Rahway New Jersey USA
| | - A M Carcaboso
- Preclinical Therapeutics and Drug Delivery Research Program Hospital Sant Joan de Déu Barcelona Barcelona Spain
| | - J M Atkinson
- Department of Pediatrics Pennsylvania State College of Medicine Hershey Pennsylvania USA
| | - A Gajjar
- Department of Oncology St. Jude Children's Research Hospital Memphis Tennessee USA
| | | | - K D Wright
- Department of Oncology St. Jude Children's Research Hospital Memphis Tennessee USA
| | - C F Stewart
- Department of Pharmaceutical Sciences St. Jude Children's Research Hospital Memphis Tennessee USA
| |
Collapse
|
9
|
Tayyem RM, Martin CR, Atkinson JM. Development and validation of a new bariatric-specific health-related quality of life instrument ′′bariatric and obesity-specific survey (BOSS)′′. J Postgrad Med 2014; 60:357-61. [DOI: 10.4103/0022-3859.143952] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
10
|
Finlay S, Bray B, Lewington AJ, Hunter-Rowe CT, Banerjee A, Atkinson JM, Jones MC. Identification of risk factors associated with acute kidney injury in patients admitted to acute medical units. Clin Med (Lond) 2013; 13:233-8. [PMID: 23760694 PMCID: PMC5922664 DOI: 10.7861/clinmedicine.13-3-233] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
In 2009, the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) report identified significant deficiencies in the management of acute kidney injury (AKI) in hospitals in the UK. Many errors arose from failure to recognise patients with AKI and those at risk of developing AKI. Currently, there is no universally accepted risk factor assessment for identifying such patients on admission to acute medical units (AMUs). A multicentre prospective observational study was performed in the AMUs of 10 hospitals in England and Scotland to define the risk factors associated with AKI and to assess quality of care. Data were collected on consecutive acute medical admissions over two separate 24-h periods. Acute kidney injury was present in 55/316 (17.7%) patients, with sepsis, hypovolaemia, chronic kidney disease (CKD) and diabetes mellitus identified as the major risk factors. Deficiencies in patient care were identified, reinforcing the continuing need to improve the management of AKI.
Collapse
Affiliation(s)
- S Finlay
- Department of Medicine, Dumfries and Galloway Royal Infirmary, Dumfries, Scotland.
| | | | | | | | | | | | | |
Collapse
|
11
|
Atkinson JM, Pullen N, Johnson TS. An inhibitor of thrombin activated fibrinolysis inhibitor (TAFI) can reduce extracellular matrix accumulation in an in vitro model of glucose induced ECM expansion. Matrix Biol 2013; 32:277-87. [PMID: 23369837 DOI: 10.1016/j.matbio.2013.01.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2013] [Revised: 01/18/2013] [Accepted: 01/18/2013] [Indexed: 12/29/2022]
Abstract
Chronic kidney disease (CKD) is characterised by the pathological accumulation of extracellular matrix (ECM) proteins leading to progressive kidney scarring via glomerular and tubular basement membrane expansion. Increased ECM synthesis and deposition, coupled with reduced ECM breakdown contribute to the elevated ECM level in CKD. Previous pre-clinical studies have demonstrated that increased plasmin activity has a beneficial effect in the protein overload model of CKD. As plasmin activation is downregulated by the action of the thrombin activated fibrinolytic inhibitor (TAFI), we tested the hypothesis that inhibition of TAFI might increase plasmin activity and reduce ECM accumulation in an in vitro model of glucose induced ECM expansion. Treatment of NRK52E tubular epithelial cells with increasing concentrations of glucose resulted in a 40% increase in TAFI activity, a 38% reduction in plasmin activity and a subsequent increase in ECM accumulation. In this model system, application of the previously reported TAFI inhibitor UK-396082 [(2S)-5-amino-2-[(1-n-propyl-1H-imidazol-4-yl)methyl]pentanoic acid] caused a reduction in TAFI activity, increased plasmin activity and induced a parallel decrease in ECM levels. In contrast, RNAi knockdown of plasmin resulted in an increase in ECM levels. The data presented here indicate that high glucose induces TAFI activity, inhibiting plasmin activation which results in elevated ECM levels in tubular epithelial cells. The results support the hypothesis that UK-396082 is able to reduce TAFI activity, normalising plasmin activity and preventing excess ECM accumulation suggesting that TAFI inhibition may have potential as an anti-scarring strategy in CKD.
Collapse
MESH Headings
- Amino Acids/pharmacology
- Animals
- Carboxypeptidase B2/antagonists & inhibitors
- Carboxypeptidase B2/genetics
- Carboxypeptidase B2/metabolism
- Cell Line
- Enzyme Inhibitors/pharmacology
- Epithelial Cells/drug effects
- Epithelial Cells/enzymology
- Epithelial Cells/pathology
- Extracellular Matrix/drug effects
- Extracellular Matrix/enzymology
- Extracellular Matrix/pathology
- Fibrinolysin/antagonists & inhibitors
- Fibrinolysin/genetics
- Fibrinolysin/metabolism
- Fibrinolysis/drug effects
- Fibrinolysis/genetics
- Gene Expression/drug effects
- Glucose/adverse effects
- Humans
- Imidazoles/pharmacology
- Kidney Tubules, Proximal/drug effects
- Kidney Tubules, Proximal/enzymology
- Kidney Tubules, Proximal/pathology
- Models, Biological
- RNA, Small Interfering/genetics
- RNA, Small Interfering/metabolism
- Rats
- Renal Insufficiency, Chronic/drug therapy
- Renal Insufficiency, Chronic/enzymology
- Renal Insufficiency, Chronic/genetics
- Renal Insufficiency, Chronic/pathology
- Thrombin/genetics
- Thrombin/metabolism
Collapse
Affiliation(s)
- J M Atkinson
- Sheffield Kidney Institute & Academic Unit of Nephrology, University of Sheffield, S10 2RX, United Kingdom
| | | | | |
Collapse
|
12
|
Atkinson JM, Tullo E, Mitchison H, Pearce MS, Kumar N. Improving the efficiency of selection to Core Medical Training: a study of the use of multiple assessment stations. J R Coll Physicians Edinb 2012; 42:101-5. [DOI: 10.4997/jrcpe.2012.202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
13
|
Atkinson JM, Barton L, Price CI. Management of acute ischaemic stroke in the acute medical unit. Acute Med 2010; 9:99-103. [PMID: 21597587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Ischaemic stroke is a major cause of death and disability which costs the NHS £2.8 billion/year. Acute stroke care is developing rapidly in line with an increasing evidence base. Intravenous thrombolysis is now recommended by NICE. For this guidance to be effectively implemented stroke must be viewed as a medical emergency by both the public and professionals. Emergency medical services must work in partnership with stroke services to establish systems and protocols which offer high quality acute stroke care. This provides challenges, both in systems design and delivery of clinical care.
Collapse
|
14
|
Atkinson JM, Siller CS, Gill JH. Tumour endoproteases: the cutting edge of cancer drug delivery? Br J Pharmacol 2008; 153:1344-52. [PMID: 18204490 PMCID: PMC2437906 DOI: 10.1038/sj.bjp.0707657] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2007] [Revised: 11/09/2007] [Accepted: 11/27/2007] [Indexed: 01/06/2023] Open
Abstract
Despite progression in anticancer drug development and improvements in the clinical utilization of therapies, current treatment regimes are still dependent upon the use of systemic antiproliferative cytotoxic agents. Although these agents are unquestionably potent, their efficacy is limited by toxicity towards 'normal' cells and a lack of tumour selective targeting, resulting in a therapeutic index which is modest at best. Consequently, the development of more tumour selective cancer treatments, with better discrimination between tumour and normal cells is unequivocally an important goal for cancer drug discovery. One such strategy is to exploit the tumour phenotype as a mechanism for tumour-selective delivery of potent therapeutics. An exciting approach in this area is to develop anticancer therapeutics as prodrugs, which are non-toxic until activated by enzymes localized specifically in the tumour. Enzymes suitable for tumour-activated prodrug development must have increased activity in the tumour relative to non-diseased tissue and an ability to activate the prodrug to its active form. One class of enzyme satisfying these criteria are the tumour endoproteases, particularly the serine- and metallo-proteases. These proteolytic enzymes are essential for tumour angiogenesis, invasion and metastasis, the major defining features of malignancy. This review describes the concept behind development of tumour-endoprotease activated prodrugs and discusses the various studies to date that have demonstrated the huge potential of this approach for improvement of cancer therapy.
Collapse
Affiliation(s)
- J M Atkinson
- Institute of Cancer Therapeutics, University of Bradford Bradford, UK
| | - C S Siller
- Institute of Cancer Therapeutics, University of Bradford Bradford, UK
| | - J H Gill
- Institute of Cancer Therapeutics, University of Bradford Bradford, UK
| |
Collapse
|
15
|
Atkinson JM, Pennington CJ, Martin SW, Anikin VA, Mearns AJ, Loadman PM, Edwards DR, Gill JH. Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: correlation of MMP-14 mRNA expression and proteolytic activity. Eur J Cancer 2007; 43:1764-71. [PMID: 17600697 DOI: 10.1016/j.ejca.2007.05.009] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2006] [Revised: 05/10/2007] [Accepted: 05/14/2007] [Indexed: 11/24/2022]
Abstract
Improved understanding of the involvement of matrix metalloproteinases (MMPs), including membrane-type MMPs (MT-MMPs), in human tumours has potential diagnostic, prognostic and therapeutic implications. We assessed the relationship between MT-MMP expression and clinicopathological parameters in human non-small cell lung cancer (NSCLC) and histologically normal lung tissue by quantitative Real Time PCR (qRT-PCR). All MT-MMPs (MMPs 14-17, 24 and 25) were detected by qRT-PCR with significantly higher MMP-14, -15 and -17 expression observed in tumour relative to normal lung specimens. MMP-16 was undetectable in normal lung but expressed in 8% tumours. MMP-15 demonstrated significant overexpression in adenocarcinomas relative to squamous cell carcinomas and normal lung tissue. MMP-14 mRNA expression strongly correlated to MMP-14 proteolytic activity in preclinical tumour models, indicating that qRT-PCR may predict MMP-14 activity levels in NSCLC. These data suggest that MMP-14, -15 and -17 may be good markers of disease, or therapeutic targets for treatment of human NSCLC.
Collapse
Affiliation(s)
- J M Atkinson
- Institute of Cancer Therapeutics, University of Bradford, Tumbling Hill Street, Bradford, West Yorkshire, BD7 1DP, UK
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Jones RB, Atkinson JM, Coia DA, Paterson L, Morton AR, McKenna K, Craig N, Morrison J, Gilmour WH. Randomised trial of personalised computer based information for patients with schizophrenia. BMJ 2001; 322:835-40. [PMID: 11290639 PMCID: PMC30562 DOI: 10.1136/bmj.322.7290.835] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVES To compare use, effect, and cost of personalised computer education with community psychiatric nurse education for patients with schizophrenia. DESIGN Randomised trial of three interventions. Modelling of costs of alternatives. PARTICIPANTS 112 patients with schizophrenia in contact with community services; 67 completed the intervention. INTERVENTIONS Three interventions of five educational sessions: (a) computer intervention combining information from patient's medical record with general information about schizophrenia; (b) sessions with a community psychiatric nurse; (c) "combination" (first and last sessions with nurse and remainder with computer). MAIN OUTCOME MEASURES Patients' attendance, opinions, change in knowledge, and psychological state; costs of interventions and patients' use of NHS community services; modelling of costs for these three, and alternative, interventions. RESULTS Rates of completion of intervention did not differ significantly (71% for combination intervention, 61% for computer only, 46% for nurse only). Computer sessions were shorter than sessions with nurse (14 minutes v 60 minutes). More patients given nurse based education thought the information relevant. Of 20 patients in combination group, 13 preferred the sessions with the nurse and seven preferred the computer. There were no significant differences between groups in psychological outcomes. Because of the need to transport patients to the computer for their sessions, there was no difference between interventions in costs, but computer sessions combined with other patient contacts would be substantially cheaper. CONCLUSIONS The computer based patient education offered no advantage over sessions with a community psychiatric nurse. Investigation of computer use combined with other health service contacts would be worth while.
Collapse
Affiliation(s)
- R B Jones
- Department of Public Health, University of Glasgow, Glasgow G12 8RZ, United Kingdom.
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
Carers have an enormous amount of responsibility for the welfare and management of people with a mental illness in Britain, and many require help if they are to continue caring. Mental health nurses may be in a key position to offer support, but they are often unclear of what is required and how it should be delivered. Existing UK nurse-led psychosocial interventions for families often focus on the needs of the patient rather than the carer. This article describes a needs-led support service that has been designed for carers whose relatives are diagnosed with schizophrenia. It recognizes the importance of a collaborative partnership between carers and nurses. In 2000, 10 mental health nurses were trained to deliver this support to carers. An evaluation is currently underway. This article outlines the principles of the training programme and how it might enable nurses to meet the carers' needs.
Collapse
Affiliation(s)
- S H Gall
- School of Nursing and Midwifery, University of Dundee
| | | | | | | |
Collapse
|
18
|
Jones R, Pearson J, McGregor S, Gilmour WH, Atkinson JM, Barrett A, Cawsey AJ, McEwen J. Cross sectional survey of patients' satisfaction with information about cancer. BMJ 1999; 319:1247-8. [PMID: 10550091 PMCID: PMC28276 DOI: 10.1136/bmj.319.7219.1247] [Citation(s) in RCA: 69] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- R Jones
- Department of Public Health, University of Glasgow, Glasgow G12 8RZ
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Jones R, Pearson J, McGregor S, Cawsey AJ, Barrett A, Craig N, Atkinson JM, Gilmour WH, McEwen J. Randomised trial of personalised computer based information for cancer patients. BMJ 1999; 319:1241-7. [PMID: 10550090 PMCID: PMC28275 DOI: 10.1136/bmj.319.7219.1241] [Citation(s) in RCA: 111] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE To compare the use and effect of a computer based information system for cancer patients that is personalised using each patient's medical record with a system providing only general information and with information provided in booklets. DESIGN Randomised trial with three groups. Data collected at start of radiotherapy, one week later (when information provided), three weeks later, and three months later. PARTICIPANTS 525 patients started radical radiotherapy; 438 completed follow up. INTERVENTIONS Two groups were offered information via computer (personalised or general information, or both) with open access to computer thereafter; the third group was offered a selection of information booklets. OUTCOMES Patients' views and preferences, use of computer and information, and psychological status; doctors' perceptions; cost of interventions. RESULTS More patients offered the personalised information said that they had learnt something new, thought the information was relevant, used the computer again, and showed their computer printouts to others. There were no major differences in doctors' perceptions of patients. More of the general computer group were anxious at three months. With an electronic patient record system, in the long run the personalised information system would cost no more than the general system. Full access to booklets cost twice as much as the general system. CONCLUSIONS Patients preferred computer systems that provided information from their medical records to systems that just provided general information. This has implications for the design and implementation of electronic patient record systems and reliance on general sources of patient information.
Collapse
Affiliation(s)
- R Jones
- Department of Public Health, University of Glasgow, Glasgow G12 8RZ.
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
BACKGROUND Education groups for people with schizophrenia have tended to concentrate on compliance with medication. This study examines impact on social behaviour and quality of life. METHOD A catchment-wide service was set up for community-based patients. Patients who indicated an interest in education groups were randomly allocated to either an education group or a waiting list control group. Those who attended groups were compared with the control group. RESULTS About one-quarter of community-based patients showed interest in attending education groups. Those who attended showed no change in mental state or compliance with medication (already high) but significant gains in quality of life, social functioning and social networks. CONCLUSIONS For patients who choose to attend education groups significant gains in social functioning and quality of life are possible without specific skills training.
Collapse
Affiliation(s)
- J M Atkinson
- Department of Public Health, University of Glasgow
| | | | | | | |
Collapse
|
21
|
Abstract
61 orthognathic surgery patients were studied (39% male, 61% female). It confirms that the group of patients we see in the West of Scotland are well adjusted psychologically and that the majority seek orthognathic surgery for aesthetic reasons. The degree of satisfaction is high (87%). Dissatisfaction is not related to sex, age or procedure. Patients who were dissatisfied tend to have higher neuroticism scores on the Eysenck Personality Inventory and those patients who had had unreal expectations of post surgical pain, numbness and swelling, were likely to express dissatisfaction with the outcome in the early stages. Several patients initially expressed some dissatisfaction with the outcome after 3 months then went on to increase their score and by 12 months became satisfied with the procedure. The authors outline the importance of adequate patient preparation prior to surgery and the use of printed literature is recommended.
Collapse
Affiliation(s)
- P M Finlay
- West of Scotland Regional Unit of Oral and Maxillofacial Surgery, Canniesburn Hospital, Glasgow
| | | | | |
Collapse
|
22
|
Polangin RF, Atkinson JM. Reinventing public health. J Fla Med Assoc 1994; 81:549-51. [PMID: 7964583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
23
|
Abstract
The use of the term sufferer to replace patient has become increasingly common. This paper examines the varied meanings implicit in the word sufferer from the Judaeo-Christian perspective. This includes the biblical themes of suffering as human nature, as punishment, as a test, as atonement and as liberation and deliverance. The consequences of these themes for the sufferer's role are examined, particularly the sufferer as accepting and the sufferer as victim. It is argued that replacing the medical model, implied by 'patient' with a theological model, implied by 'sufferer' does not free the person from the constraints of a damaging label.
Collapse
|
24
|
Atkinson JM. Male obstetricians and their patients. BMJ 1993; 306:861. [PMID: 8490405 PMCID: PMC1677270 DOI: 10.1136/bmj.306.6881.861-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
25
|
Abstract
The effect of Ca++ mobilizing agonists arginine vasopressin and phenylephrine on Na+/H+ exchange was studied in freshly isolated hepatocytes and isolated perfused rat livers. The activity of Na+/H+ exchange was determined from the rate of H+ efflux, 22Na uptake and pHi recovery. Arginine vasopressin and phenylephrine stimulated H+ efflux and 22Na uptake in isolated rat hepatocytes and increased the rate of pHi recovery from acid-loaded hepatocytes. These effects were inhibited by amiloride. Arginine vasopressin- and phenylephrine-induced increases in H+ efflux were also dependent on extracellular Na+. Arginine vasopressin- and phenylephrine-induced increases in intracellular Ca++ concentration, H+ efflux, 22Na uptake and intracellular pH recovery were decreased in hepatocytes preloaded with the Ca(++)-buffering agent [bis-(2-amino-5-methylphenoxy)-ethane-N,N,N',N'-tetraacetic acid] (MAPTA). Na+/H+ exchange-dependent intracellular pH recovery from cytosolic acidification was stimulated by thapsigargin, which increases intracellular calcium concentration by inhibiting endoplasmic reticulum Ca++ ATPase. Arginine vasopressin- and phenylephrine-induced increases in intracellular pH recovery were not dependent on extracellular Ca++ and were inhibited by calmidazolium, a calmodulin inhibitor. Arginine vasopressin and phenylephrine also increased H+ efflux in the absence but not in the presence of amiloride in perfused rat livers without affecting biliary HCO3- excretion. These results indicate that arginine vasopressin and phenylephrine activate Na+/H+ exchange in rat hepatocytes, an effect mediated in part by intracellular Ca++ and calmodulin kinase. Furthermore, sinusoidal Na+/H+ exchange does not appear to be involved in biliary HCO3- excretion.
Collapse
Affiliation(s)
- M S Anwer
- Department of Medicine, Tufts University School of Veterinary Medicine, North Grafton, Massachusetts 01536
| | | |
Collapse
|
26
|
Anwer MS, Branson AU, Atkinson JM. Mechanism of inhibition of hepatic bile acid uptake by amiloride and 4,4'-diisothiocyano-2,2'-disulfonic stilbene (DIDS). Biochem Pharmacol 1991; 42 Suppl:S135-41. [PMID: 1768270 DOI: 10.1016/0006-2952(91)90403-r] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The mechanisms by which amiloride and 4,4'-diisothiocyano-2,2'-disulfonic stilbene (DIDS) inhibit hepatic uptake of cholate and taurocholate (TC) were investigated in isolated rat hepatocytes. Amiloride inhibited Na(+)-dependent uptake of cholate and TC only when hepatocytes were preincubated with amiloride, indicating an indirect effect of amiloride. Time-dependent studies showed that the inhibition of bile acid uptake was associated with a parallel increase in intracellular Na+ concentration ([Na+]i). Although amiloride decreased intracellular pH, this decrease preceded amiloride-induced inhibition of bile acid uptake and increase in [Na+]i. Amiloride inhibited bile acid uptake, decreased membrane potential, and increased [Na+]i with comparable concentration dependency. DIDS inhibited Na(+)-dependent uptake of cholate and TC non-competitively. Neither DIDS nor amiloride inhibited Na(+)-independent uptake of cholate and TC. These results indicate that amiloride inhibits Na(+)-dependent cholate and TC uptake by decreasing the transmembrane Na(+)-gradient, and further support the hypothesis that two different transporters may be involved in hepatic bile acid uptake by Na(+)-dependent and Na(+)-independent mechanisms.
Collapse
Affiliation(s)
- M S Anwer
- Department of Medicine, Tufts University School of Veterinary Medicine, North Grafton, MA 01536
| | | | | |
Collapse
|
27
|
|
28
|
Kay EJ, Millar K, Blinkhorn AS, Atkinson JM. The prevention of dental disease: changing your patients' behaviour. Dent Update 1991; 18:245-8. [PMID: 1810775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
This article aims to give practitioners a framework to help their patients establish lasting and healthy dental habits and eliminate harmful ones. The advice given is practical rather than theoretical in nature, and is intended to assist dentists in the development of the appropriate skills, so as to be able to persuade their patients to change their behaviour and thereby control dental disease.
Collapse
Affiliation(s)
- E J Kay
- Dental School, University of Dundee
| | | | | | | |
Collapse
|
29
|
Atkinson JM, Millar K, Kay EJ, Blinkhorn AS. Stress in dental practice. Dent Update 1991; 18:60-4. [PMID: 1915991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The life of a GDP is stressful, and the reasons why dentists may experience stress in their chosen profession are many and varied. This article discusses the causes of stress, and outlines some strategies for coping with it.
Collapse
|
30
|
Millar K, Atkinson JM, Blinkhorn AS, Kay EJ. Helping anxious adult patients. Dent Update 1991; 18:18, 20-2, 24-5. [PMID: 1936426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
31
|
Blinkhorn AS, Kay EJ, Atkinson JM, Millar K. Advice for the dental team on coping with the nervous child. Dent Update 1990; 17:415-9. [PMID: 2088793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
It is increasingly recognized that the provision of dental care should not be seen in isolation from the psychological make-up and social background of the patient. The General Dental Council has recently approved the report of its Working Party giving guidance on the teaching of the behavioural sciences (psychology and sociology) in the dental curriculum. One of the members of the Working Party was Professor Keith Millar. In this five-part series edited by Professor Millar we will cover the practical application of behavioural science in dentistry, covering communication with patients, ways to change your patients' behaviour, the management of anxious adult and child patients, and stress in dentistry. This first article offers some advice on coping with the nervous child.
Collapse
|
32
|
Abstract
Bile acid-induced HCO3(-)-rich choleresis may be due to primary activation of sinusoidal Na(+)-H+ exchange or to biliary reabsorption of unconjugated bile acid. To test these hypotheses, we studied the effect of cholate and taurocholate (TC) (infused at 10 mumol/min for 20 min) on net H+ efflux, biliary [HCO3-], and bile flow in perfused rat livers and on intracellular pH (pHi) in isolated hepatocytes. Cholate, but not TC, produced HCO3(-)-rich choleresis. Amiloride and taurine decreased cholate-induced choleresis and HCO3- excretion and biliary excretion of unconjugated cholate. Amiloride, but not taurine, decreased cholate-induced net H+ efflux. Both cholate and TC (200-750 microM) decreased pHi. Cholate was metabolized to a polar compound, most likely cholate glucuronide, in the presence of amiloride. These results are consistent with the hypothesis that the biliary reabsorption of unconjugated cholate may be involved in HCO3(-)-rich choleresis. Amiloride also inhibited net hepatic uptake and biliary excretion of cholate and TC without affecting hepatic content of bile acids. It is suggested that amiloride may decrease the maximal excretion rate of cholate and TC. Since cholate and TC induce amiloride-sensitive net H+ efflux and decrease pHi, it appears that cholate and TC activate Na(+)-H+ exchange indirectly by decreasing pHi.
Collapse
Affiliation(s)
- M S Anwer
- Department of Medicine, Tufts University School of Veterinary Medicine, North Grafton, Massachusetts 01536
| | | | | |
Collapse
|
33
|
Abstract
Ursodeoxycholate (UDC)-induced HCO3- -rich choleresis may be due to activation of sinusoidal Na+-H+ exchange followed by an increase in intracellular pH (pHi) and HCO3- excretion via canalicular Cl- -HCO3- exchange. To test this hypothesis, we studied the effect of UDC and tauroursodeoxycholate (TUDC) on net H+ efflux from perfused rat livers and pHi in isolated hepatocytes in the presence and absence of amiloride. UDC-induced increases in biliary HCO3- concentration and excretion were inhibited by amiloride. However, these increases were temporally associated with an initial decline in H+ efflux and pHi followed by a gradual recovery toward base line. The initial decline in H+ efflux was associated with a rapid uptake of UDC. Amiloride inhibited only the recovery phases of H+ efflux and pHi. TUDC increased amiloride-sensitive H+ efflux without affecting biliary [HCO3-] and decreased pHi in the presence but not in the absence of amiloride. Amiloride decreased TUDC-induced choleresis and HCO3- excretion most likely by decreasing TUDC excretion. TUDC decreased biliary [Cl-] and increased hepatic O2 uptake more than UDC. We conclude that a rapid influx of UDC in the protonated form decreases pHi and net H+ efflux initially. The recovery phase is due to Na+-H+ exchange activated by decreased pHi and possibly by UDC and increased cellular respiration. TUDC indirectly stimulates Na+-H+ exchange most likely by increasing cellular respiration. UDC-induced HCO3- -rich choleresis, which is observed at a time when both net H+ efflux and pHi are less than control values, is unlikely to be due to a direct activation of Na+-H+ exchange.
Collapse
Affiliation(s)
- M S Anwer
- Department of Medicine, Tufts University School of Veterinary Medicine, North Grafton, Massachusetts 01536
| | | | | |
Collapse
|
34
|
Abstract
Some patients with schizophrenia are not told their diagnosis. The moral, clinical and practical issues involved in telling or not telling the patient are discussed. In some cases a relative is told the diagnosis but not the patient. The implications for the family and clinical outcome are outlined. A case history illustrating some of these issues is presented.
Collapse
Affiliation(s)
- J M Atkinson
- Department of Community Medicine, University of Glasgow
| |
Collapse
|
35
|
|
36
|
Abstract
This article describes a trial of a low-cost, readily disseminatable weight-control program ("Waistline") which uses behavioral, social support, and community strength-building principles. Participants meet for 12 weeks in small, lay-led groups in community settings, and use prepackaged materials designed specifically for those of modest education. Results from 407 participants are presented, showing a mean postcourse weight loss of 5.6 kg (12.3 lb) and a low attrition rate (9-12%). In a subsample followed up at 12 months (N = 96), 80% of this loss had been maintained. A comparison group ("Slimline," N = 26) lost 1.27 kg (2.8 lb) and had an attrition rate of 31-46%. The Waistline results are comparable to those obtained by more intensive and expensive behavioral programs, and demographic data show that those of relatively low educational attainment are well represented. The potential of this approach for cheap, noncommercial dissemination of weight-control programs on a population basis is noted.
Collapse
|
37
|
Atkinson JM. The role of medical photography in safe-guarding the potential wandering patient. J Biol Photogr 1983; 51:107-8. [PMID: 6677632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
38
|
Atkinson JM. Experience with a microcomputer in a medical illustration department. J Audiov Media Med 1983; 6:15-16. [PMID: 6841903 DOI: 10.3109/17453058309154362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|
39
|
Abstract
Serratia marcescens can become a formidable nosocomial (hospital acquired) pathogen, and is reported increasingly in the world literature. However, it is only a recently recognized problem in Australia. Serratia can carry an antibiotic-resistance plasmid, and, after entry of the organism into very sick patients, it may be hard or impossible to eliminate. Initial experience of Serratia in 34 consecutive cases isolated in a three-months period is presented. Rapid increase in the number of Serratia infections occurred after the appearance of a resistant strain. Urinary infection was the commonest presentation (91% of cases). The presence of an indwelling urinary catheter in a debilitated patient was the major predisposing factor. Significant bacteraemia followed in four cases with one death. Contamination of burns (surfaces) and surgical wounds was found in four cases. Serratia strains were found to be highly resistant to most antimicrobial agents in routine sensitivity testing, 20% being fully resistant to all tested agents, and nalidixic acid being the most effective inhibitor in the remainder. With bacteriocin typing of Serratia, two types were found to be dominant. These two bacteriocin types were not identified among strains isolated from other sources such as soil, water and local hospitals. Pharyngeal carriage was found in only one case, but faecal excretion of Serratia was found in 11 cases and may be a significant portal of dissemination. Cross-infection from a hospital reservoir of resistant organisms is postulated. A model of cross-infection is also proposed, and methods of control are discussed. In view of the established danger of Serratia in the hospital setting, its isolation can no longer be ignored.
Collapse
|
40
|
|
41
|
Abstract
1. Electrical stimulation of the thoraco-lumbar spinal nervous outflow in the pithed rat preparation produces a fall in arterial blood pH.2. A component of the acidaemic response results from stimulation of skeletal muscle, since the acidaemic response is reduced when contractions of muscle are blocked with gallamine.3. The residual acidaemic response in gallamine-treated rats is reduced by adrenalectomy, suggesting that catecholamines liberated from the adrenal medulla may mediate part of the effect.4. Guanethidine reduces the acidaemic response remaining in adrenalectomized, gallamine-treated rats, suggesting that the effect of noradrenaline released from sympathetic nerve endings contributes to the fall in pH.5. Neither phenoxybenzamine nor propanolol alone significantly reduces the acidaemic response in gallamine-treated rats, but a combination of the two antagonists almost abolishes the effect. Hence the acidaemia is mediated through effects of catecholamines on both alpha- and beta-adreno-receptors.6. Since acidaemia affects responses to sympathetic nerve stimulation and sympathomimetic amines, the significance of these observations is discussed with reference to the use of the pithed rat preparation for assessment of drugs affecting adrenergic mechanisms.
Collapse
|
42
|
Atkinson JM, Dusting GJ, Rand MJ. Acidaemia produced by sympathomimetic amines and sympathetic nerve stimulation. J Physiol 1973; 229:6P-8P. [PMID: 4689993 PMCID: PMC1350402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
|
43
|
Atkinson JM, Dusting GJ, Rand MJ. Acidosis induced by catecholamines and reduction of cardiovascular responses to catecholamines in acidosis. Aust J Exp Biol Med Sci 1972; 50:847-59. [PMID: 4658842 DOI: 10.1038/icb.1972.82] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
44
|
|
45
|
|
46
|
|
47
|
Atkinson JM, Pun LQ, Rand MJ. The effect of directly and indirectly acting sympathomimetic amines on bronchospasm in the guinea-pig during CO2 inhalation. J Pharm Pharmacol 1970; 22:488-95. [PMID: 4395052 DOI: 10.1111/j.2042-7158.1970.tb10551.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Abstract
The bronchodilator effects of nine sympathomimetic amines were tested by reduction of histamine-induced bronchospasm in guinea-pigs. Their order of potency was: isoprenaline > adrenaline > noradrenaline > orciprenaline > ethylnoradrenaline > phenylephrine > amphetamine = tyramine > ephedrine. In guinea-pigs ventilated with 10% CO2 in air, there was a marked decrease in the bronchoconstrictor activity of histamine. Under these conditions, isoprenaline, adrenaline, noradrenaline and orciprenaline were as effective as bronchodilators as they had been in guinea-pigs ventilated with air, ethylnoradrenaline was less effective, phenylephrine, amphetamine and tyramine were completely inactive, and ephedrine potentiated the bronchoconstrictor action of histamine. After returning the guinea-pigs to ventilation with air, the bronchoconstrictor activity of histamine and the bronchodilator effects of the sympathomimetic amines were restored. The cardiovascular effects of histamine and of all the sympathomimetic amines used were diminished during ventilation with 10% CO2 in air and were restored after ventilation with air was resumed.
Collapse
|
48
|
Abstract
Abstract
Observations were made of the effects of adrenaline, isoprenaline and orciprenaline on the blood pressure, heart rate and configuration of the ECG in cats. The effects of single injections of these amines in producing a rise in heart rate and a fall in blood pressure were reduced during the intravenous infusion of any one of them: the pressor response to injected adrenaline was enhanced during an infusion. Combinations of these amines did not produce changes in the configuration of the ECG. These experiments were motivated by allegations of acute toxic effects on the cardiovascular system of large doses, or of combinations, of sympathomimetic bronchodilators in asthma. No evidence of deleterious effects of interactions was obtained.
Collapse
|
49
|
Atkinson JM. On the sociology of suicide. Sociol Rev 1968; 16:83-92. [PMID: 5760869 DOI: 10.1111/j.1467-954x.1968.tb01293.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|
50
|
|